Journal of Antimicrobial Chemotherapy (2000) 46, 35-39
© 2000 The British Society for Antimicrobial Chemotherapy
Pivmecillinam in the treatment of urinary tract infections
Health Sciences Centre, GC430-820 Sherbrook Street, Winnipeg, MB, Canada R3A 1R9
The efficacy of pivmecillinam for empirical treatment of acute uncomplicated urinary tract infection (UTI) was initially reported in clinical trials published in the 1970s and 1980s. Bacteriological cure rates observed in these trials were consistently >85%, and studies of different dosing regimens suggested that a 3 day course was appropriate. Comparative studies reported that pivmecillinam was equivalent to other antimicrobial agents in terms of clinical and bacteriological outcomes. These studies also documented that pivmecillinam was effective for treatment of Staphylococcus saprophyticus infections, was acceptable for use in pregnancy and was well tolerated. Subsequent widespread use of pivmecillinam in Scandinavian countries has led to a body of clinical experience which confirms the efficacy and safety of this antimicrobial agent in the treatment of acute cystitis. Recently, two large, prospective, randomized, double-blind, multi-centre clinical trials have been completed to assist in defining the role of this antimicrobial agent in the treatment of acute cystitis. A comparison of 3 day courses of pivmecillinam or norfloxacin, both at 400 mg bd, showed higher bacteriological cure rates with norfloxacin but generally similar clinical outcomes. A second, dose-ranging study found that pivmecillinam, given bd for 7 days, led to superior bacteriological and clinical outcomes at short-term follow-up than the 3 day regimen. Pooling bacteriological outcomes from the two studies showed similar outcomes with 7 days of pivmecillinam 200 mg bd or 3 days of norfloxacin 400 mg bd. The shorter, 3 day, course achieved similar short-term clinical outcomes to 7 days of pivmecillinam and 3 days of norfloxacin in women aged 
50 years. These recent studies confirm earlier reports and clinical experience that pivmecillinam is effective and well tolerated for the treatment of acute cystitis in women.
* Corresponding author. Tel: +1-204-787-7772; Fax: +1-204-787-3159; E-mail: lnicolle{at}hsc.mb.ca
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  M. Wootton, T. R. Walsh, L. Macfarlane, and R. A. Howe Activity of mecillinam against Escherichia coli resistant to third-generation cephalosporins J. Antimicrob. Chemother., November 13, 2009; (2009) dkp404v1. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Wiuff and D. I. Andersson Antibiotic treatment in vitro of phenotypically tolerant bacterial populations J. Antimicrob. Chemother., February 1, 2007; 59(2): 254 - 263. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. Odenholt and O. Cars Pharmacodynamics of moxifloxacin and levofloxacin against Streptococcus pneumoniae, Staphylococcus aureus, Klebsiella pneumoniae and Escherichia coli: simulation of human plasma concentrations after intravenous dosage in an in vitro kinetic model J. Antimicrob. Chemother., November 1, 2006; 58(5): 960 - 965. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Thomas, M. J. Weinbren, M. Warner, N. Woodford, and D. Livermore Activity of mecillinam against ESBL producers in vitro J. Antimicrob. Chemother., February 1, 2006; 57(2): 367 - 368. [Full Text] [PDF]
|
|
|
|
 |
|
 R. R. Regoes, C. Wiuff, R. M. Zappala, K. N. Garner, F. Baquero, and B. R. Levin Pharmacodynamic Functions: a Multiparameter Approach to the Design of Antibiotic Treatment Regimens Antimicrob. Agents Chemother., October 1, 2004; 48(10): 3670 - 3676. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. Odenholt, E. Lowdin, and O. Cars Postantibiotic, Postantibiotic Sub-MIC, and Subinhibitory Effects of PGE-9509924, Ciprofloxacin, and Levofloxacin Antimicrob. Agents Chemother., October 1, 2003; 47(10): 3352 - 3356. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Jayaram, S. Gaonkar, P. Kaur, B. L. Suresh, B. N. Mahesh, R. Jayashree, V. Nandi, S. Bharat, R. K. Shandil, E. Kantharaj, et al. Pharmacokinetics-Pharmacodynamics of Rifampin in an Aerosol Infection Model of Tuberculosis Antimicrob. Agents Chemother., July 1, 2003; 47(7): 2118 - 2124. [Abstract] [Full Text] [PDF]
|
|